HR6994

This bill directly amends the Controlled Substances Act to allow telehealth practitioners to prescribe approved mental health controlled substances and controlled substances for opioid use disorder after at least one telehealth evaluation. It also broadens the definition of a 'covering practitioner' to include telehealth evaluations within the previous 90 days. This legislative change removes a significant barrier to access for mental health and addiction treatment, expanding the scope of practice for telehealth providers and increasing patient access to necessary medications. The money trail flows directly to telehealth platforms and pharmacies. Telehealth companies will see increased utilization and new patient acquisition as the regulatory hurdle for prescribing controlled substances via virtual visits is lowered. Pharmacies, both brick-and-mortar and online, will experience a higher volume of prescriptions for these controlled substances. The mechanism is regulatory relief, directly expanding the services that can be provided remotely, thereby increasing revenue opportunities for companies operating in this space. Historically, during the COVID-19 pandemic, temporary waivers allowed for expanded telehealth prescribing of controlled substances. This led to a surge in telehealth adoption and revenue for companies like Teladoc Health ($TDOC) and Amwell ($AMWL). For example, in 2020, Teladoc's revenue grew 98% year-over-year, and Amwell's revenue increased 77% year-over-year, largely driven by increased telehealth utilization and regulatory flexibility. This bill codifies and expands upon those temporary measures, establishing a permanent framework for telehealth prescribing of controlled substances. Specific winners include major telehealth providers such as Teladoc Health ($TDOC) and Amwell ($AMWL), which will see increased demand for their platforms. Livongo Health, now part of Teladoc, will also benefit from expanded mental health service offerings. Large pharmacy chains like CVS Health ($CVS) and Walgreens Boots Alliance will process more prescriptions. Health insurers such as Humana ($HUM) and UnitedHealth Group ($UNH) will see increased claims for telehealth mental health services, potentially leading to higher utilization but also improved patient outcomes. The bill's sponsor, Rep. Dunn, a Republican from Florida, indicates bipartisan potential for this type of healthcare access legislation, suggesting a higher likelihood of passage. What happens next is committee consideration. The bill has been referred to the Committee on Energy and Commerce and the Committee on the Judiciary. Given the sponsor's position and the policy area, it will likely move through committee hearings and markups. If it passes committee, it will then proceed to a House floor vote. The timeline for passage is uncertain but could occur within the 119th Congress.